TP-0903

TP-0903 是一种有效的选择性 AXL 抑制剂，IC50 为 27 nM。TP-0903 可非常有效地诱导凋亡。

Target	Value
Axl (Cell-free assay)	27 nM

在胰腺癌细胞(PSN-1)中，TP-0903表现出强烈的抗增殖活性，IC50为6 M。TP-0903通过有效抑制Aurora A和B，诱导强烈的G2/M阻滞。在来自CLL患者的CLL B细胞中，TP-0903通过靶向作用于磷酸化Axl，剂量依赖性诱导大量细胞凋亡，并且克服了CLL BMSC-介导的对CLL B细胞凋亡的保护作用。

在成年大鼠海马体中，SAG (2.5 nM)的脑室内给药显著增加新生细胞的数量，并延长海马细胞的生存。在小鼠中，SAG (20 μg/g, i.p.)有效防止GC-诱导的新生儿小脑发育异常。 一种高效性的、选择性的Axl受体酪氨酸激酶抑制剂，IC50：27nM。
Dubermatinib is a potent and selective AXL inhibitor. TP-0903 induces massive apoptosis in CLL B cells with LD50 values of nanomolar ranges. Combination of TP-0903 with BTK inhibitors augments CLL B-cell apoptosis AXL overexpression is a reoccurring theme observed in multiple tumor types that have acquired resistance to various agents. Treatment of cancer cells with TP-0903 reverses the mesenchymal phenotype in multiple models and sensitizes cancer cells to treatment with other targeted agents. Administration of TP-0903 either as a single agent or in combination with BTK inhibitors may be effective in treating patients with CLL.